Loading Events

« All Events

  • This event has passed.

Combination Products: Finding Pathways to Market When Both Drug and Device Systems Are in Play

April 7, 2021 @ 4:00 pm - 6:00 pm EDT


Full Length

Highlight Preview

This forum focuses on how to advance combination products. Many significant advances in disease treatment come from combination products, which enable delivery of drugs in a more precise, controlled way. The intersection of devices and drugs is an exciting, profitable arena for innovative concepts to achieve commercialization. We will describe headwinds facing combination products companies and get sage advice on how to overcome them.

Apr 7, 2021
4:00 – 6:00 PM (EDT)

United States

William Munger


Combination Products

Finding pathways to market when both drug and device systems are in play

Successful commercialization of combination products is an exciting, profitable growth arena for innovative concepts.

Estimated Market Size in 2024
= $178 Billion (CAGR 7.9%)

Source: Grand View Research

But how to do it right?

Our panelists will share their critical knowledge and experience with you. Hear their talks & then speak with them afterwards in post-Forum Networking!

Many significant advances in disease treatment come from combination products, which enable delivery of drugs in a more precise, controlled way.

You will learn about:

  • Real life experiences of combination product startups
  • Talking to investors
  • Reimbursement strategies
  • Navigating FDA regulatory challenges and roadblocks
  • Finding success in a system designed for drug and devices, but not necessarily combined

Wed, April 21
4:00 – 6:00 PM (EST)
4:00 – 4:30 General Networking
4:30 – 5:30 Presentations
5:30 – 6:00 ‘Meet the Speakers’ & More Networking

Forum Fees
$0 – Members (all categories)
$0 – Sponsors / Student
$0 – Covid Hardship
$20 – Non-Member




Tony Voiers
CEO, Advanced Chemotherapy Technologies (ACT)

ACT is developing a combo product for non-resectable pancreatic cancer.

Topic: Firsthand account of the challenges unique to early-stage combination product companies, such as talking to investors.


Mike John
VP, Cardiovascular Regulatory Affairs at MCRA; Former Chief, Interventional Cardiology Devices Branch, Division of CV Devices, FDA

Topic: How to navigate the regulatory landscape for combination products, what makes them different, and how to (hopefully) avoid pitfalls.



John D. McDermott, Jr, MBA
Senior Director, Reimbursement Strategy, MCRA

Topic: Reimbursement–what is needed for success with combination products.




Elazer R. Edelman
Director, Institute of Medical Engineering and Science, Director, Clinical Research Center at MIT; Current occupant of the Edward J. Poitras Chair as Professor of Medical Engineering and Science






April 7, 2021 Forum

Highlights Preview Short – Watch on Vimeo


April 7, 2021
4:00 pm - 6:00 pm EDT
Event Categories:




MDG Boston